SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (16460)4/14/2005 8:53:51 PM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Who else benefits

I think all the pharma benefit to some extent. This was a cloud hanging over Lilly, and by extension over the rest of them. There was this sense that "no patent is safe" and that just added to the already heightened risk profile of the sector.

Peter



To: tom pope who wrote (16460)4/14/2005 9:29:32 PM
From: Ian@SI  Respond to of 52153
 
Probably every company with IP to protect benefits, but especially those in big Pharma. I don't know that the generics should really lose a bunch after the initial reaction. There's still lots of pickings as some major blockbusters legitimately lose their patent protection.

IMO,
Ian


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News